What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial).

What question did this study set out to answer?

To evaluate the impact of lenalidomide before apheresis on T cell fitness and pharmacodynamics in multiple myeloma patients.

December 8, 2025Blood

Impact of lenalidomide pre-apheresis on markers of T cell fitness and pharmacodynamic biomarkers in newly diagnosed multiple myeloma patients with suboptimal response to autologous stem cell transplantation

View Full Paper

Ask AI

Bookmark

Authors

JWJ G WongHarvard University SNSonash NayeeBristol-Myers Squibb (Sweden)DBDebashree BasudharBristol-Myers Squibb (Sweden)

Discussion

Member takes

Implication

Cross-cohort analysis demonstrates improved T cell fitness in myeloma patients following lenalidomide, suggesting potential for better CAR T therapy outcomes.

Key Points

To evaluate the impact of lenalidomide before apheresis on T cell fitness and pharmacodynamics in multiple myeloma patients.
Cross-cohort analysis of patients with multiple myeloma undergoing autologous stem cell transplantation and receiving lenalidomide pre-apheresis.
Immune profiling using Mass Cytometry by Time-of-Flight and immunoassays to assess T cell markers and cytokines.
Characterization of drug product features using high-parameter flow cytometry.
Cohort with lenalidomide showed improved T cell fitness and favorable cytokine profiles compared to the control cohort.
Higher levels of IL2, IL7, and perforin were noted in the lenalidomide cohort, supporting enhanced CAR T activity.
93.3% of lenalidomide patients exhibited better clearance of tumor biomarker sBCMA compared to 77.4% in the control.

Cite This Study

Wong et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cffa https://doi.org/10.1182/blood-2025-95

View Full Paper

Ask AI

Bookmark

Implication

Cross-cohort analysis demonstrates improved T cell fitness in myeloma patients following lenalidomide, suggesting potential for better CAR T therapy outcomes.

Impact of lenalidomide pre-apheresis on markers of T cell fitness and pharmacodynamic biomarkers in newly diagnosed multiple myeloma patients with suboptimal response to autologous stem cell transplantation

Discussion

Member takes

Implication

Key Points

Cite This Study

Impact of lenalidomide pre-apheresis on markers of T cell fitness and pharmacodynamic biomarkers in newly diagnosed multiple myeloma patients with suboptimal response to autologous stem cell transplantation

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider